Trupanion Inc. (TRUP) Options Positioning, Max Pain & Unusual Sweeps

Per the Roarable RQD rating, TRUP scores 63 out of 100, graded C, with the verdict "Roarable Hold — Fair / Balanced Risk-Reward." The score is built from five pillars, each out of 20. The fundamental cash engine pillar scores 10/20, reflecting ROIC of 3.1% and FCF yield of 5.69%; for an investor, this signals that the business currently generates modest returns on capital relative to its valuation. The whale 13F flow pillar scores 13/20, indicating institutional accumulation and options positioning that is supportive but not dominant. The insider conviction pillar scores 11/20 based on SEC Form 4 and Congressional PTR cluster flow, a middling read on whether insiders are signaling confidence. The macro regime fit pillar scores 14/20, with beta of 1.0 and sector sensitivity; the stock moves in line with the broader market, offering neither a defensive cushion nor elevated volatility. The forensic balance sheet pillar scores 15/20, supported by Altman Z 3.17, Piotroski F 8/9, and Debt/Equity 0.27, the strongest pillar and a reason the balance sheet is not the primary concern. Taken together, a prospective investor evaluating the stock today faces a balanced setup: the balance sheet is sound, but valuation is elevated against thin current profitability, so upside depends on margin expansion continuing to materialize.

Trupanion Inc. is a NASDAQ-listed issuer in the Health Care sector and Medical Specialities industry, per the profile. The company's product lines, customer base, and revenue model are not described in the source data. Per the SEC financials, FY 2025 revenue was $1439.3M, indicating a sizable operating scale. Not available in source data for further detail on how the company makes money.

Per the SEC financials, the company moved from operating and net losses in FY 2023 and FY 2024 to a profit in FY 2025, with net income of $19.4M. Per the market data, gross margin is 16.1%, operating margin 1%, and net margin 1.4%, with ROIC of 3.1%, so profitability remains thin. Per the Roarable RQD rating, the Altman Z-Score is 3.17 and the Piotroski F-Score is 8/9, and the Debt/Equity ratio is 0.27. Cash declined from $160.3M to $138.0M while debt declined from $127.5M to $101.8M over FY 2024 to FY 2025.

The news wire contains six items, all tagged as market wire and yellow-flagged, with no company-specific fundamental event described in the headlines. One item reports that the COO, John Gallagher, sold $12,550 in company stock, a small insider sale per the Investing.com report. Another headline describes the stock rebounding on a margin focus and asks whether it remains cheap, per Simply Wall St. A Yahoo Finance item notes earnings are expected to grow. A MarketBeat item cites an average target price of $38.40. A TradingView item covers estimates. The first item is a general stock-quote page. Risk watch items include the insider sale and the thin current margins. The butterfly supply-chain graph reports no supply chain and no proprietary signals.

Per the Butterfly Supply-Chain Graph, the supply chain is not available and there are no butterfly links or proprietary signals. Upstream and downstream dependencies are not available in source data. Sector correlations beyond the Health Care and Medical Specialities classification are not available in source data. Second-order bottlenecks are not available in source data.

• What is the company's revenue composition and customer base, since no business description beyond sector classification is provided?
• What drove the swing from FY 2024's net loss of $-9.6M to FY 2025's net income of $19.4M, and is the margin improvement durable?
• Why is EPS reported as N/A for all periods, and what is the EPS trajectory behind the $0.44 TTM figure?
• What is the source and composition of the FY 2023 gap in cash and debt data?
• What do the insider sale and institutional positioning signals indicate about management's view of the valuation at a 68.2 P/E?